SLC19A4P
Putative solute carrier family 19 member 4
Also known as: CB083_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for SLC19A4P in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
150 residues, UniProt reviewed canonical sequence.
>Q53S99|SLC19A4P
1 MEDYALTFGI NPFIALMIQP IVTMTVVDNQ GLGLPVDIQH KAKPSPKASQ MLPPDLGPPS
61 FQNLLSPSEK LEPWDPGMRK LTVQTCGLTF IHPAGHGLCH PTAEASAETL SSTALNRPSV
121 REGACNEKST ENKKPQDSVL WSHSRWFQGNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SLC19A4P can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.68
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SLC19A4P as an antibody target. Whether an autoantibody or antibody against SLC19A4P could matter depends on whether native SLC19A4P is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SLC19A4P is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SLC19A4P as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...